The 21st Century Cures Act: Is It Worth the Cost for Lifesciences?
This article explores whether the long-term the Act’s benefits will outweigh the costs.
The 21st Century Cures Act (“Act”), passed by the U.S. Congress and signed into law by former U.S. President Obama on December 13, 2016, legislatively boosts funding for a host of government research and regulatory programs including $4.8 billion for the National Institutes
of Health (“NIH”); $1.8 billion to accelerate research for cancer; $1.6 billion for brain diseases including Alzheimer’s; $500 million in funding for the U.S. Food and Drug Administration (“FDA”) and $1 billion in grants to assist States deal with opioid abuse.
To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In
Related StoriesAn FCA Journey - Allergan to Pay $53M to DOJGenentech & Escobar: Using Materiality to Escape False Claims LiabilityChicago’s Attempt to Regulate Drug Reps - A Real Public Health Initiative or Simple Revenue Generator?
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
More News: Allergy | American Health | Brain | Brain Cancers | Cancer | Cancer & Oncology | Funding | Government | Grants | Health Management | International Medicine & Public Health | Men | National Institutes of Health (NIH) | Neurology | Obama | Politics | Research | Substance Abuse | USA Health